Cingulate Inc
NASDAQ:CING
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ningxia Xiaoming Agriculture & Animal Husbandry Co Ltd
SZSE:300967
|
CN |
|
BCM Resources Corp
XTSX:B
|
CA |
|
Nyxoah SA
XBRU:NYXH
|
BE |
|
Guangdong Topstar Technology Co Ltd
SZSE:300607
|
CN |
|
Probe Metals Inc
XTSX:PRB
|
CA |
|
Sunflag Iron and Steel Co Ltd
NSE:SUNFLAG
|
IN |
|
Kodiak Copper Corp
XTSX:KDK
|
CA |
|
H
|
Hanjia Design Croup Co Ltd
SZSE:300746
|
CN |
|
Balrampur Chini Mills Ltd
NSE:BALRAMCHIN
|
IN |
|
B
|
Brain+ A/S
CSE:BRAINP
|
DK |
|
Efuel EFN Corp
OTC:EFLN
|
US |
|
ASX Ltd
ASX:ASX
|
AU |
|
P
|
Promotora de Informaciones SA
SWB:PZ41
|
ES |
|
Full House Resorts Inc
NASDAQ:FLL
|
US |
Cingulate Inc
Other
Cingulate Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cingulate Inc
NASDAQ:CING
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other
-$260m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
16%
|
CAGR 10-Years
-16%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other
-$128m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-30%
|
|
|
Pfizer Inc
NYSE:PFE
|
Other
-$459m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other
-$131m
|
CAGR 3-Years
18%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other
-$772m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-31%
|
|
Cingulate Inc
Glance View
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The company is headquartered in Kansas City, Kansas. The company went IPO on 2021-10-07. The firm is focused on the development, manufacturing and commercialization of pharmaceutical products that utilize precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles that improves the lives of patients suffering from a multitude of commonly diagnosed conditions. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The firm is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). Its CTx-1301 and CTx-1302 drug candidates both contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form. Its CTx-1301 and CTx-1302 that are being developed for the treatment of ADHD, in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+).
